Pivotal Trial of Vosaroxin/Cytarabine Combo Fails to Meet Primary Endpoint in AML Patients

Mixed results have been reported from a pivotal phase III, randomized, double-blind, placebo-controlled study of vosaroxin and cytarabine in patients with first-relapsed or refractory acute myeloid leukemia . The trial enrolled 711 patients, who were stratified for age, geography, and disease status.

http://ift.tt/1oKaKN9